Explore

Trendline Trendline
Pathos AI Expands Cancer Drug Pipeline with Deals from Alphamab and AstraZeneca

Pathos AI Expands Cancer Drug Pipeline with Deals from Alphamab and AstraZeneca

Pathos AI Expands Cancer Drug Pipeline with Deals from Alphamab and AstraZeneca
Trendline Trendline
Pathos AI and Alphamab Oncology Collaborate on Cancer Drug Development

Pathos AI and Alphamab Oncology Collaborate on Cancer Drug Development

Pathos AI and Alphamab Oncology Collaborate on Cancer Drug Development
Trendline Trendline
Pathos AI Secures Global Licensing for JSKN016 from Alphamab Oncology

Pathos AI Secures Global Licensing for JSKN016 from Alphamab Oncology

Pathos AI Secures Global Licensing for JSKN016 from Alphamab Oncology
Trendline Trendline
Precision Oncology Drives Growth in Molecular Cancer Therapeutics Market

Precision Oncology Drives Growth in Molecular Cancer Therapeutics Market

Precision Oncology Drives Growth in Molecular Cancer Therapeutics Market
Trendline Trendline
Gilead Sciences Reports Strong Revenue Growth Despite Losses in Q2 2026

Gilead Sciences Reports Strong Revenue Growth Despite Losses in Q2 2026

Gilead Sciences Reports Strong Revenue Growth Despite Losses in Q2 2026
Trendline Trendline
Faeth Therapeutics Reports Financial Growth and Advances in Cancer Trials

Faeth Therapeutics Reports Financial Growth and Advances in Cancer Trials

Faeth Therapeutics Reports Financial Growth and Advances in Cancer Trials
Trendline Trendline
Pathos AI Collaborates with AstraZeneca to Advance Breast Cancer Therapy

Pathos AI Collaborates with AstraZeneca to Advance Breast Cancer Therapy

Pathos AI Collaborates with AstraZeneca to Advance Breast Cancer Therapy
Trendline Trendline
ORIC Pharmaceuticals Reports Wider Q2 Loss Amid Prostate Cancer Trial Progress

ORIC Pharmaceuticals Reports Wider Q2 Loss Amid Prostate Cancer Trial Progress

ORIC Pharmaceuticals Reports Wider Q2 Loss Amid Prostate Cancer Trial Progress
Trendline Trendline
Billionaire Stanley Druckenmiller's Investment in Revolution Medicines Yields Significant Returns

Billionaire Stanley Druckenmiller's Investment in Revolution Medicines Yields Significant Returns

Billionaire Stanley Druckenmiller's Investment in Revolution Medicines Yields Significant Returns
Trendline Trendline
Sellas Life Sciences Sees Institutional Investment Surge Amid Phase 3 Trial Progress

Sellas Life Sciences Sees Institutional Investment Surge Amid Phase 3 Trial Progress

Sellas Life Sciences Sees Institutional Investment Surge Amid Phase 3 Trial Progress
Trendline Trendline
BioNTech Appoints Guido Oelkers as New CEO to Drive Future Growth

BioNTech Appoints Guido Oelkers as New CEO to Drive Future Growth

BioNTech Appoints Guido Oelkers as New CEO to Drive Future Growth
Trendline Trendline
CRISPR Therapeutics Reports Progress in Gene-Edited Therapies

CRISPR Therapeutics Reports Progress in Gene-Edited Therapies

CRISPR Therapeutics Reports Progress in Gene-Edited Therapies